PATIENT GROUP DIRECTION (PGD)
|
|
- Janice Wilson
- 5 years ago
- Views:
Transcription
1 PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by: Name: Daniel Barry Position: Lead Pharmacist Mental Health Chichester Locality Name: Dr Davie Robertson Position: General Practitioner, HMP Ford Name: Stacey Brewis Position: DART Nurse, HMP Ford Patient Group Direction authorised by: Name: Dr Tim Ojo Position: Medical Director, on behalf of the organisation Name: Jed Hewitt Position: Chief Pharmacist Name: Diane Hull Position: Director of Nursing Standards & Safety Date Protocol agreed January 2017 Proposed review date September 2018 Date Protocol expires January
2 PATIENT GROUP DIRECTION DETAILS Staff characteristics Professional qualification: NMC Registered Nurse At least 3 months post registration experience in a substance misuse team Evidence of training in basic life support and anaphylaxis, updated annually Has attended a PGD foundation course Has successfully completed the 'Key topics of Pharmacy' questionnaire for Supply of naloxone hydrochloride injection Has read the HMP Ford Standard Operating Procedure for Takehome Naloxone Hydrochloride CLINICAL DETAILS Aims Diagnosis / condition treated Criteria for inclusion Criteria for exclusion Cautions Clinical features of an This patient group direction (PGD) will allow registered nurses the authority to supply naloxone to named clients who are being released and have been identified as being at future risk of opioid overdose The aim of supply is to reduce the occurrence of drug related deaths in this client group Supply of naloxone to treat actual or suspected overdose due to an opioid substance, to reverse the action of opioids such as heroin, methadone, morphine (inc MST ), pethidine, dihydrocodeine (DF118 ) or buprenorphine (Temgesic, Subutex ) It does not matter which opioid was taken or whether it was legal or not If overdose is suspected then naloxone should be given Naloxone can be used even if evidence of an opioid overdose is lacking, so should be used if there is a suspicion that an individual s respiratory depression or impaired level of consciousness is due to an excess of opioid Clients at risk of opioid overdose, who have demonstrated awareness and understanding of naloxone supply Clients must have undertaken appropriate training in the use of Prenoxad 1mg/1ml injection Clients must successfully complete the Take-away Naloxone Hydrochloride (Prenoxad 1mg/1ml injection 2ml syringe) Competence Questionnaire for Clients Naloxone will not be supplied to clients: Who have not undertaken the approved training Where valid consent for supply is not obtained Note: There are no clinical exclusions from treatment where opioid overdose is suspected Exclusion may result in the death of the patient The client must understand the short acting nature of naloxone and an apparently successful outcome after injection of naloxone may be followed later by a return to respiratory depression and overdose The client should be advised of the requirement to contact the emergency services wherever opioid overdose is suspected For the purposes of the PGD, the injection may only be administered by intramuscular injection Naloxone may cause hypersensitivity reactions in a small number of susceptible individuals Medical advice must be sought as soon as possible from a doctor if a recipient develops any signs of hypersensitivity Suspected or actual opioid overdose is indicated by symptoms, such as 2
3 actual or suspected overdose due to an opioid substance Actions to be taken for patients who are excluded from supply or do not wish to receive a supply of naloxone under the PGD pinpoint pupils, respiratory depression and reduced level of consciousness In addition the individual may be difficult to rouse, unresponsive to painful stimuli, unconscious, snoring, have shallow slow breathing, blue lips; or may present very drowsy When spoken to they may be difficult, and then some minutes later may be unable to respond to questions He/she may be a known drug user or there may be evidence that they are using opiates or are an injecting drug user (eg injection sites, track marks, drug paraphernalia or collateral reports) Refer to current edition of British National Formulary wwwbnforg for latest information on cautions If a client is excluded from treatment under this PGD it will be explained to them that naloxone can only be supplied under the PGD following completion and demonstration of understanding of the approved training The client should be provided with details of how to access training Clients who are not eligible to receive a supply of naloxone may still attend basic life support and naloxone administration training Advice should be given on alternative treatment strategies including harm reduction and overdose prevention The client should be advised of the requirement to contact the emergency services wherever overdose is suspected The client should be referred to an appropriate healthcare professional and / or advised on available treatment services if appropriate Any action or referral should be noted in the client s SystmOne record Generic name Formulation and route Strength Dose(s) and frequency of administration Duration of treatment Legal status Storage DESCRIPTION OF TREATMENT Naloxone Hydrochloride 2mL pre-filled syringe for intramuscular injection 1mg/mL A single dose of 04 mg (04mL) should be administered immediately upon an individual being suspected of having taken an opioid overdose The dose should be administered intramuscularly into the outer thigh or muscles of the upper arm It may be administered through clothing if necessary If the patient has not responded or if respiratory function deteriorates a further dose of 04 mg (04mL) should be administered; this can be repeated at 2-3 minute intervals Clients should be advised not to exceed 5 doses Prescription Only Medicine (POM) Store below 25 C After use, any unused solution should be discarded immediately Any unused product or waste material (including needles) should be disposed of in accordance with local requirements 3
4 Adverse effects Advice to be given to the client Procedure to follow on issue of Prenoxad 2mg/2ml injection Administration of naloxone in opioid overdose is a life-saving intervention and should not be delayed However abrupt reversal of opioid effects by the administration of naloxone may cause the following reactions: In patients who are physically dependent on opioids, rapid reversal of opioid effects may precipitate an acute withdrawal syndrome, inducing nausea, vomiting, sweating, tachycardia, hyperventilation, hypertension and tremor Common reactions include hypotension, hypertension, ventricular tachycardia, dizziness and headache In patients with pre-existing cardiac disease or in those taking potentially cardiotoxic drugs, serious adverse effects have been reported such as pulmonary oedema, myocardial ischaemia, hypotension, hypertension, ventricular tachycardia and fibrillation The client should be informed of importance of contacting ambulance services by dialling 999 at the earliest opportunity where opioid overdose is suspected Clients must understand the short acting nature of naloxone and an apparently successful outcome after injection of naloxone may be followed later by return of respiratory depression and overdose On arrival of the ambulance, individuals are instructed to advise ambulance staff of how the patient has responded and details of any adverse effects Ensure the client has undertaken an approved Take Home Naloxone Training Programme Explain treatment and course of action Highlight information included in the Manufacturers Patient Information Leaflet Where this is unavailable, or unsuitable, sufficient information should be given to the client in a language that they can understand Store the product in a cool, dry place Protect from light Keep syringes in a sealed container Use within expiry date on product Clients will be trained in the safe storage and handling of the product and safe disposal of needles following naloxone injection Advise client on procedures to obtain resupplies of naloxone after their current supply has been used, lost or expired Advice given will be recorded in the client s SystmOne record Advice should be given on what to expect and what to do for major and minor reactions The Prenoxad injection pack already contains needles Label the Prenoxad injection with a pre-printed HMP Ford label, completing the Patient name and Issue date sections on the label 4
5 AUDIT TRAIL Records required for a documented audit trail Authorisation Nurses can be authorised to supply Naloxone by an Authorised Person, namely a Clinical Nurse Manager, Substance Misuse Service Team Lead or Pharmacist working for or on behalf of Sussex Partnership NHS Foundation Trust Reason for giving or record why drug not supplied SystmOne patient record including exclusion criteria Scanned, completed copy of the Client Consent and Record Form for the Supply of the Prenoxad 2mg/2ml injection to Take Home Scanned copy of the Take-away Naloxone Hydrochloride (Prenoxad 1mg/1ml injection 2ml syringe) Competence Questionnaire for Clients after the client has successfully completed it Trust Incident Form To be completed in the event of a suspected adverse drug reaction The incident must be reported immediately to the relevant member of staff Report on suspected Adverse Drug Reactions (Yellow form in back of the BNF) To be completed for a significant adverse event by a doctor, pharmacist or nurse 5
6 COMPETENCY Designation (tick appropriate box) NMC Registered Nurse Competency/Qualifications (tick when checked) Professional qualification: NMC Registered Nurse At least 3 months post registration experience in a substance misuse team Evidence of training in basic life support and anaphylaxis, and to remain updated annually Has attended a PGD foundation course Has successfully completed the 'Key topics of Pharmacy' questionnaire for Supply of naloxone hydrochloride injection Has read the HMP Ford Standard Operating Procedure for Take-home Naloxone Hydrochloride Evidence checked by: Name Designation Signature Review of competency Two years or following a significant change in the Patient Group Direction Competency expires Two years or following a significant change in the Patient Group Direction 6
7 AUTHORISATION OF PROFESSIONAL TO USE THE PATIENT GROUP DIRECTION SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Date valid from: Date of expiry: This confirms that I: Name: understand the PGD have received the necessary education and training am of the opinion I am competent to implement the PGD effectively agree to work within the PGD SIGNATURE OF AUTHORISED PERSON Name: REFERENCES 1 Patient Group Direction (PGD) for the Supply and/or Administration of Naloxone Hydrochloride Injection by Registered Nurses Working in Community and Inpatient Substance Misuse Teams Helen Manuell Sussex Partnership NHS Foundation Trust Patient Group Direction for the Supply of Naloxone Injection by Appropriately Registered Nurses and Pharmacists to Individuals at Risk of Opioid Overdose in NHS Grampian NHS Grampian accessed 08/07/ prenoxadhtm?q=prenoxad&t=search&ss=text&tot=1&p=1#php33748-prenoxad accessed 08/07/2016 7
8 KEY ASPECTS OF PHARMACY QUESTIONNAIRE Supply of naloxone hydrochloride injection (To be completed without access to the PGD or drug text books, eg BNF) Professional's name: Job Title: 1 Symptoms/criteria under which the patient will be eligible for treatment under the PGD 2 Forms and strengths available 3 Mode of action 4 Exclusion criteria 5 Doses per injection 6 Maximum doses per episode 7 Repeat dose frequency 8 Route of administration 9 What potentially significant side effects are there? 10 What potentially significant drug interactions are there? 11 What written/verbal advice must be given to client? I confirm that at the time of completion the answers provided showed an acceptable level knowledge Name: Designation: 8
9 9
10 Take-away Naloxone Hydrochloride (Prenoxad 1mg/1ml injection 2ml syringe) Competence Questionnaire for Clients 1 What is Naloxone used for? 2 How does Naloxone work? 3 How long does Naloxone last once it has been administered? 4 What are the risks of using Naloxone? 5 What are a person s symptoms when they have overdosed on opioid drugs? 10
11 6 What should you do before you administer Naloxone? 7 Describe how to administer naloxone 8 What is the route of administration for Naloxone? 9 How much is a single dose of Naloxone? 10 How much time should have passed before you administer another dose? 11 What is the maximum number of doses that you can administer? 11
12 12 What should you do after you administer Naloxone? 13 Describe how to put someone into the recovery position 12
Community Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss
More informationVersion Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by:
PATIENT GROUP DIRECTION (PGD) FOR THE INPATIENT ADMINISTRATION OF ORAL LORAZEPAM TO WORKING AGE AND OLDER PEOPLE (includes persons in a Place of Safety suite) Version Number: 5 Patient Group Direction
More informationVersion Number: 02. Patient Group Direction drawn up by: Jayne Bruce - Deputy Director of Nursing Standards and Safety Sussex
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF INFLUENZA VACCINE BY REGISTERED NURSES (PEER VACCINATORS) TO STAFF WORKING FOR SUSSEX PARTNERSHIP NHS FOUNDATION TRUST Version Number: 02 Patient
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationSAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS. Version 5 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SYMPTOMS OF COUGHS Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or
More informationTake-home Naloxone for Opioid Overdose Guideline and Procedures
Hull & East Riding Prescribing Committee Take-home Naloxone for Opioid Overdose Guideline and Procedures Document Reference Version Number Author/Lead Job Title Draft version numbers are generated by the
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationPublic Health Dorset Prenoxad (Naloxone) Supply Standard Operating Procedure (SOP)
Public Health Dorset Prenoxad (Naloxone) Supply Standard Operating Procedure (SOP) 1 Introduction 1.1 Purpose This SOP aims to provide guidance on the supply of take home naloxone, in the form of Prenoxad
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: Medicines Procedure: Patient Group Directions for the Administration of Hepatitis B Vaccine for SABP Drug and Alcohol Teams. PURPOSE OF PROCEDURE:
More informationpatient group direction
CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationSAMPLE. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie
Patient Group Direction for the Supply or Administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate Vaccine (Infanrix-IPV-HIB) to children
More informationNaloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative
Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative Background: In September 2015, Illinois passed a new law, PA99-0480, expanding access to the opioid
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationSAMPLE. This direction was authorised on 4/5/2007. The direction will be reviewed by 4/5/2009
Patient Group Direction for the Supply and Administration of Flumazenil 100microgram Injection To Patients requiring reversal of oversedation due to midazolam in association withendoscopy attending Endoscopy
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationTake Home Naloxone Report on supply and use to reverse an overdose
Take Home Naloxone Report on supply and use to reverse an overdose 2012-2016 1 Contents 1. Introduction 2. How the Take Home Naloxone Programme works 3. How information is collected 4. Patients supplied
More informationThis document expires on Patient Group Direction No. VI 5
Patient Group Direction (PGD) for The Administration of Combined Adsorbed Diphtheria, Tetanus, Pertussis, (Acellular Component) and Inactivated Poliomyelitis Vaccine (Infanrix-IPV ) to children aged between
More informationNaloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no
THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any
More informationpatient group direction
SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationExpiry Date: September 2009 Template Version: Page 1 of 7
GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationBe courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off.
1 2 EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. 3 4 5 6 Course Outline Introduction
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorized by their organization to practice under it. The most recent and in date final signed version
More informationPatient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02
More informationNaloxone Intranasal EMT OPTIONAL SKILL. Cell Phones and Pagers. Course Outline 09/2017
EMT OPTIONAL SKILL Naloxone Intranasal Cell Phones and Pagers Be courteous to your classmates! Please set your cell phones and/or pagers to silent or turn them off. Course Outline Introduction and Overview
More informationConsultation Group: See page 7. Review Date: June Uncontrolled when printed. Version 1. Executive Sign-Off
Guidance For Drug Treatment Services In Grampian Undertaking Supply Of Naloxone To People At Risk Of Opioid Overdose, Significant Others And Services In Contact With Those At Risk Co-ordinators: Specialist
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationby registered nurses employed by NHS Hertfordshire or Hertfordshire GP Practices and signatories to the PGD
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationGUIDELINES FOR THE USE OF NALOXONE INJECTION FEBRUARY 2018
GUIDELINES FOR THE USE OF NALOXONE INJECTION FEBRUARY 2018 Guidelines for the use of naloxone injection in acute services Policy title Policy reference PHA58 Policy category Clinical Relevant to All medical,
More informationPatient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services
Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen
More informationThis document expires on Patient Group Direction No. VI 7
Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed
More informationGG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationGG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationpatient group direction
DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care
More informationNHS Lothian Patient Group Direction Version: 007. Title: Levonorgestrel 1500mcg for Emergency Contraception
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LEVORGESTREL 1500mcg FOR EMERGENCY CONTRACEPTION BY DESIGNATED HEALTHCARE PROFESSIONALS PROVIDING SEXUAL HEALTH SERVICES, UNSCHEDULED CARE SERVICES OR
More informationPatient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationClinical Condition Indication:
Patient Group Direction ( for Health Care GG&C PGD ref no: 2018/1611 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition
More informationTemplate Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices
Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining
More informationADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME
STANDARD OPERATING PROCEDURE ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME First Issued July 08 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote
More informationNaloxone Standing Order for Opioid Overdose
Naloxone Standing Order for Opioid Overdose By: Christine Trusky, PharmD Candidate 2016, Wilkes University Continuing Education Activity Details: Activity Type: Knowledge-based Target Audience: Pharmacists
More informationClinical Condition Indication:
GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationNHS Lothian Patient Group Direction Version: 006
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION AND SUPPLY OF AZITHROMYCIN FOR TREATMENT OF CHLAMYDIA (PATIENT OR PARTNER) OR CONTACTS OF NON-SPECIFIC URETHRITIS (NSU) OR PELVIC INFLAMMATORY DISEASE (PID)
More informationThis document expires on Patient Group Direction No. VI 11
Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses
More informationPGD No Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil - September 2012
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION Supply / Administration of: By: Pharmacists Azithromycin 250mg capsules for Chlamydia In: Community Pharmacy It is the responsibility of the professional working under this PGD
More informationOpioids - Fentanyl - Naloxone. Public Health Nurse
Opioids - Fentanyl - Naloxone Public Health Nurse What are Opioids? Opioids are a family of drugs that treat pain and can cause sleepiness. Prescription (legal) Opioids fall into 3 main categories: 1.
More informationPGD5717. Director of Quality & Clinical Performance. Therèsa Moyes
PGD5717 Patient Group Direction Administration of Nicotine Lozenges 4mg, Sublingual Tablets 2mg or Mouth Spray By Registered Nurses employed as by South Staffordshire & Shropshire Healthcare Foundation
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationGuideline for the use of Naloxone in Adults
Guideline for the use of Naloxone in Adults Controlled document This document is uncontrolled when downloaded or printed Reference number Version 1 Authors WHHT: MM098 Date ratified February 2016 Committee:
More informationPatient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018
Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start 1 st July 2015 Expiry 30 th June 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: BLACKPOOL
More informationAdministration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors.
Administration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors. Special notes PPD is an unlicensed medicine and therefore
More informationCALDERDALE PRIMARY CARE TRUST
CALDERDALE PRIMARY CARE TRUST PATIENT GROUP DIRECTION FOR THE SUPPLY AND ADMINISTRATION OF MEDICINES BY NON- MEDICAL PERSONNEL Progestogen-only emergency contraception for use in Community Pharmacies APPROVED
More informationSALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department
More informationThis document expires on Patient Group Direction Number VI 19
Patient Group Direction (PGD) for The Administration of Pneumococcal Polysaccharide Vaccine (PPV, Pneumovax II ) to adults over 65 years and at risk groups aged 2 years and over, by Registered Nurses employed
More informationADMINISTRATION OF INSULIN
STANDARD OPERATING PROCEDURE ADMINISTRATION OF INSULIN Issue History First issued April 2012 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote the safe administration
More informationPatient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationGG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Active immunisation
More informationExpiry Date: July 2009 Template Version: Page 1 of 7
Salbutamol nebules YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT NPGD2007/355 (supersedes 2004/177) Clinical Condition Indication: Inclusion
More informationpatient group direction
REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic
More informationPatient Group Direction (PGD)
Patient Group Direction (PGD) Supply of Nitrofurantoin for uncomplicated Urinary Tract Infections in females aged 16 years and over (Telford and Wrekin and Shropshire Pharmacies Only) For the supply of
More informationTHIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
Patient Group Direction for Pneumococcal polysaccharide vaccine VERSION: PNEUMOCOCCAL POLY-2013.1 (Pneumovax II ) Start 1 st May 2013 Expiry 30 th April 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED
More informationPrescription only medicines (POMs)
Prescription only medicines (POMs) 2017 Learning objectives Explain the legal framework with which registered health care professionals can administer prescription only medicines Define the role and limitations
More informationGuidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian
Title: Identifier: Guidance For The Use Of Naltrexone In The Maintenance Of Abstinence in Formerly Opioid Dependent Adults By Clinicians Working Within NHS Grampian NHSG/Guide/NHSG_NaltexMA_885 Replaces:
More informationpatient group direction
MORPHINE SULPHATE (Oral) v01 1/8 MORPHINE SULPHATE (Oral) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic)
More informationPatient Group Direction (PGD)
Patient Group Direction (PGD) Supply of Clarithromycin for Impetigo in patients aged one year and over who are allergic to Penicillin (Staffordshire Pharmacies Only) For the supply of Clarithromycin by
More informationOlanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)
1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance
More informationPATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)
PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) VALID FROM: 1 st July 2016 REVIEWED DATE: 30 th June 2019 This
More informationClinical Condition Indication:
GG&C PGD ref no: 2016/1366 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationThe prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics
Tablet Press EXTRA The prescribing newsletter for GPs, nurses and pharmacists NHS Northamptonshire Failure to respond to first choice antibiotics March 2017 Use of Buccolam (buccal midazolam) for breakthrough
More informationpatient group direction
NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationHEPATITIS A + TYPHOID VACCINE
GG&C PGD ref no: 2017/1522 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Indicated for active immunisation
More informationAdrenaline 1mg in 10mL (1:10,000) Pre-filled syringe 3 Amiodarone 300mg/10mL Pre-filled syringe 5
Quick Reference Guide for: Cardiac Arrest Medicines Box (BLUE) Please Note: Any medicines given must form part of an Airway, Breathing, Circulation, Disability and Exposure (ABCDE) Assessment (9)999 must
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationPackage leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate
Package leaflet: Information for the patient Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because
More informationPATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine
PHE publications gateway number: PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine For the supply of
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS. Version 1 (reviewed unchanged January 2018)
GROUP PROTOCOL FOR THE MANAGEMENT OF CONSTIPATION IN PATIENTS IN CLOZAPINE CLINICS Version 1 (reviewed unchanged January 2018) RATIFYING COMMITTEE Drugs and Therapeutics Group DATE ORIGINALLY 29 th October2014
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017
Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationGrampian Naloxone Programme Pre-reading Materials (Adapted from materials supplied with the kind permission of the Scottish Drugs Forum)
Grampian Naloxone Programme Pre-reading Materials (Adapted from materials supplied with the kind permission of the Scottish Drugs Forum) This presentation aims to refresh knowledge on the causes, risk
More informationService Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian
Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2017
Patient Group Direction For Supply Of Paracetamol Oral Suspension 120mg/5mL For Prevention Of Post Immunisation Fever Following Administration Of Meningococcal Group B Vaccine (Bexsero ) By Community Pharmacists
More informationPatient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within.
NHS Grampian Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian Lead Author: Consultation Group: Approver: Medicines
More informationPrescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)
Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree
More informationMedicines Protocol RECTAL DIAZEPAM
Medicines Protocol RECTAL DIAZEPAM RECTAL DIAZEPAM v2.0 1/6 Protocol Details Version 2.0 Legal category Staff grades POM Registered Paramedic Registered Nurse Specialist Paramedic (Urgent and Emergency
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Prenoxad 0.91 mg/ml solution for injection in a pre-filled syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active substance is
More informationPATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists
PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of
More informationGG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against rotavirus.
More informationGG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Individuals requiring active immunisation
More information